

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAAXB1648

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:02:34 ON 24 APR 2008

=> FIL MEDLINE BIOSIS CAPLUS CA USPATFULL
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.63	0.63

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 15:04:03 ON 24 APR 2008

FILE 'BIOSIS' ENTERED AT 15:04:03 ON 24 APR 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:04:03 ON 24 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CA' ENTERED AT 15:04:03 ON 24 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:04:03 ON 24 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s Flomerfelt or Gress
L1 272 FLOMERFELT OR GRESS

=> s spatial
L2 785133 SPATIAL

=> s spatial or (stromal (w) protein (w) associated (w) with (w) thymii)
L3 785133 SPATIAL OR (STROMAL (W) PROTEIN (W) ASSOCIATED (W) WITH (W) THYM
II)

=> s spatial and (stromal (w) protein (w) associated (w) with (w) thymii)
L4 3 SPATIAL AND (STROMAL (W) PROTEIN (W) ASSOCIATED (W) WITH (W)
THYMII)

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5 2 DUP REM L4 (1 DUPLICATE REMOVED)

=> d ibib ab l5 1-2

L5	ANSWER 1 OF 2	MEDLINE on STN	DUPLICATE 1
ACCESSION NUMBER:	2007684720	MEDLINE	
DOCUMENT NUMBER:	PubMed ID: 17961552		
TITLE:	Neuronal distribution of spatial in the developing cerebellum and hippocampus and its somatodendritic association with the kinesin motor KIF17.		
AUTHOR:	Irla Magali; Saade Murielle; Fernandez Carla; Chasson Lionel; Victorero Genevieve; Dahmane Nadia; Chazal Genevieve; Nguyen Catherine		
CORPORATE SOURCE:	INSERM-ERM206, laboratoire TAGC, Case 928, Parc Scientifique de Luminy, 13288 Marseille Cedex 9, France.		
SOURCE:	Experimental cell research, (2007 Dec 10) Vol. 313, No. 20, pp. 4107-19. Electronic Publication: 2007-09-20. Journal code: 0373226. ISSN: 0014-4827.		
PUB. COUNTRY:	United States		
DOCUMENT TYPE:	Journal; Article; (JOURNAL ARTICLE)		

(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200801
ENTRY DATE: Entered STN: 21 Nov 2007
Last Updated on STN: 24 Jan 2008
Entered Medline: 23 Jan 2008

AB We identified the Spatial (Stromal Protein Associated with Thymii and Lymph-node) gene from an adult thymus mouse library of cDNA clones. By RT-PCR, we reported that Spatial was highly expressed in restricted areas of the central nervous system. Here, we characterize the precise cellular localization of Spatial during mouse brain development in the cerebellum, hippocampus and cortex. Five different transcript isoforms have been described for Spatial and among those, only Spatial-epsilon and -beta present a tightly controlled expression. In the cerebellum, Spatial expression is detected in the external precursor granular layer and persists as these cells migrate and differentiate to form the internal granular layer. It is also expressed in differentiating Purkinje cells with a specific somatodendritic distribution. Spatial expression in the hippocampus is spatially and temporally regulated: it is first expressed in the CA3 field, then in CA1 and later in the dentate gyrus. Interestingly, Spatial-beta expression tightly overlaps with the beginning of neuronal differentiation in both structures. Using cultured hippocampal neurons, we show that Spatial also exhibits a somatodendritic distribution and it is concentrated in some synaptic regions. Moreover, the vesicle-like cellular distribution of Spatial protein in dendrites is similar to that described for the kinesin motor protein KIF17. Immunofluorescence analyses show that Spatial colocalizes with KIF17 in dendrites of hippocampal neurons in primary culture. Additionally, coimmunoprecipitation experiments of endogenous proteins from hippocampus confirmed that Spatial and KIF17 physically interact. These findings suggest that Spatial may play a role in neuronal morphogenesis and synaptic plasticity through its interaction with the kinesin motor KIF17 in dendrites.

L5 ANSWER 2 OF 2 MEDLINE on STN
ACCESSION NUMBER: 2004361846 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15236666
TITLE: Genomic organization and the tissue distribution of alternatively spliced isoforms of the mouse Spatial gene.
AUTHOR: Irla Magali; Puthier Denis; Granjeaud Samuel; Saade Murielle; Victorero Genevieve; Mattei Marie-Genevieve; Nguyen Catherine
CORPORATE SOURCE: ERM 0206 INSERM, Case 928, Parc Scientifique de Luminy, F-13288 Marseille Cedex 9, Universite de la mediterranee, faculte de science de Luminy, France.. irla@tagc.univ-mrs.fr
SOURCE: BMC genomics, (2004 Jul 5) Vol. 5, No. 1, pp. 41.
Electronic Publication: 2004-07-05.
Journal code: 100965258. E-ISSN: 1471-2164.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200503
ENTRY DATE: Entered STN: 22 Jul 2004
Last Updated on STN: 23 Mar 2005

Entered Medline: 22 Mar 2005

AB BACKGROUND: The stromal component of the thymic microenvironment is critical for T lymphocyte generation. Thymocyte differentiation involves a cascade of coordinated stromal genes controlling thymocyte survival, lineage commitment and selection. The "Stromal Protein Associated with Thymii And Lymph-node" (Spatial) gene encodes a putative transcription factor which may be involved in T-cell development. In the testis, the Spatial gene is also expressed by round spermatids during spermatogenesis. RESULTS: The Spatial gene maps to the B3-B4 region of murine chromosome 10 corresponding to the human syntenic region 10q22.1. The mouse Spatial genomic DNA is organised into 10 exons and is alternatively spliced to generate two short isoforms (Spatial-alpha and -gamma) and two other long isoforms (Spatial-delta and -epsilon) comprising 5 additional exons on the 3' site. Here, we report the cloning of a new short isoform, Spatial-beta, which differs from other isoforms by an additional alternative exon of 69 bases. This new exon encodes an interesting proline-rich signature that could confer to the 34 kDa Spatial-beta protein a particular function. By quantitative TaqMan RT-PCR, we have shown that the short isoforms are highly expressed in the thymus while the long isoforms are highly expressed in the testis. We further examined the inter-species conservation of Spatial between several mammals and identified that the protein which is rich in proline and positive amino acids, is highly conserved. CONCLUSIONS: The Spatial gene generates at least five alternative spliced variants: three short isoforms (Spatial-alpha, -beta and -gamma) highly expressed in the thymus and two long isoforms (Spatial-delta and -epsilon) highly expressed in the testis. These alternative spliced variants could have a tissue specific function.

=> s stromal (w) protein (w) associated (w) with (w) thymii
L6 3 STROMAL (W) PROTEIN (W) ASSOCIATED (W) WITH (W) THYMII

=> s spatial and uba3
L7 6 SPATIAL AND UBA3

=> dup rem 17
PROCESSING COMPLETED FOR L7
L8 5 DUP REM L7 (1 DUPLICATE REMOVED)

=> d ibib ab 18 1-5

L8 ANSWER 1 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2007:284036 USPATFULL
TITLE: Spatial for Altering Cell Proliferation
INVENTOR(S): Flomerfelt, Francis A., Kensington, MD, UNITED STATES
Gress, Ronald E., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007248589	A1	20071025
APPLICATION INFO.:	US 2003-579879	A1	20031118 (10)
	WO 2003-US36874		20031118
			20060517 PCT 371 date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KLARQUIST SPARKMAN, LLP, 121 S.W. SALMON STREET, SUITE #1600, PORTLAND, OR, 97204-2988, US		
NUMBER OF CLAIMS:	66		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 19 Drawing Page(s)

LINE COUNT: 4796

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This disclosure provides methods useful for altering cell proliferation by modifying SPATIAL activity in cells. In some methods, thymocyte numbers in subjects with disease-associated immunodeficiencies are increased by administering an agent that inhibits SPATIAL activity. Also provided are methods useful for increasing thymocyte number in a subject by administering an agent that interferes with an interaction between SPATIAL and Uba3. In other methods, cell growth is inhibited by introducing or expressing a SPATIAL or SPATIAL-related polypeptide or nucleic acid in one or more cell(s), such as neoplastic cell(s). Further provided are methods of identifying agents that modify (for example, inhibit) SPATIAL expression or activity, or which interfere with an interaction between SPATIAL and Uba3 polypeptides, and therefore which are useful in influencing thymocyte number.

L8 ANSWER 2 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2007:17468 USPATFULL

TITLE: Biomarkers for huntington's disease

INVENTOR(S): Krainc, Dimitri, Boston, MA, UNITED STATES

PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007015183	A1	20070118
APPLICATION INFO.:	US 2006-440574	A1	20060525 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-687134P	20050603 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	4727	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates, in part, to specific genes and set of genes that are selectively expressed in Huntington's disease and their use for the diagnosis and staging of HD. Additionally, the selectively expressed genes are useful in methods to assess HD pathogenesis in cells, tissues, and subjects, and in the assessment of the efficacy of HD therapeutics.

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:588483 CAPLUS

DOCUMENT NUMBER: 143:111316

TITLE: Mouse protein SPATIAL that interacts with Uba3 for altering cell proliferation and thymocyte numbers and use thereof for drug screening and treatment of disease-associated immunodeficiencies

INVENTOR(S): Flomerfelt, Francis A.; Gress, Ronald E.

PATENT ASSIGNEE(S): The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060364	A2	20050707	WO 2003-US36874	20031118
WO 2005060364	A3	20060112		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20070248589	A1	20071025	US 2006-579879	20060517

PRIORITY APPLN. INFO.: WO 2003-US36874 W 20031118

AB This disclosure provides methods useful for altering cell proliferation by modifying SPATIAL activity in cells. In some methods, thymocyte nos. in subjects with disease-associated immunodeficiencies are increased by administering an agent that inhibits activity of protein SPATIAL (stromal protein associated with thymii and lymph nodes). Specifically disclosed are cDNA and protein sequences of SPATIAL short and long isoforms. In one embodiment, SPATIAL expression has been found to influence and control thymocyte number in disease-associated immunodeficiencies. For example, it has been found that inhibition of SPATIAL expression leads to surprisingly rapid thymocyte accumulation and differentiation in thymii of severely immunodeficient subjects who have received bone marrow transplantation. Furthermore, SPATIAL is shown to regulate the cell cycle by specifically interacting with Uba3 (between region 183 to 308). This interaction disrupts the binding between Uba3 and AppBP1, thus SPATIAL is believed to inhibit the NEDD8 conjugation (neddylation) pathway and inhibit cells from dividing. In specific examples, an agent that interferes with a SPATIAL/Uba3 interaction promotes proliferation of cells, such as thymic stromal cells, which cells then enhance the production and differentiation of thymocytes. Also provided are methods useful for increasing thymocyte number in a subject by administering an agent that interferes with an interaction between SPATIAL and Uba3. In other methods, cell growth is inhibited by introducing or expressing a SPATIAL or SPATIAL-related polypeptide or nucleic acid in one or more cell(s), such as neoplastic cell(s). Further provided are methods of identifying agents that modify (for example, inhibit) SPATIAL expression or activity, or which interfere with an interaction between SPATIAL and Uba3 polypeptides, and therefore which are useful in influencing thymocyte number

L8 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2005:298974 USPATFULL

TITLE: Method for diagnosing pancreatic cancer

INVENTOR(S): Nakamura, Yusuke, Yokohama-shi, JAPAN
Katagiri, Toyomasa, Shinagawa-ku, JAPAN
Nakagawa, Hidewaki, Shinagawa-ku, JAPAN

PATENT ASSIGNEE(S): Oncotherapy Science, Inc., Kawasaki-shi, JAPAN
(non-U.S. corporation)

The University of Tokyo, Bunkyo-ku, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005260639	A1	20051124
APPLICATION INFO.:	US 2005-90739	A1	20050324 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2003-JP11817, filed on 17 Sep 2003, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-555809P	20040324 (60)
	US 2003-450889P	20030228 (60)
	US 2002-414872P	20020930 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	6547	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Objective methods for detecting and diagnosing pancreatic cancer (PNC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of PNC-associated gene that discriminates between PNC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of pancreatic cancer, methods of treating pancreatic cancer and method of vaccinating a subject against pancreatic cancer.

L8 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2004:66006 USPATFULL
 TITLE: DNA array sequence selection
 INVENTOR(S): Lorenz, Matthias, Bethesda, MD, United States
 PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6706867	B1	20040316
APPLICATION INFO.:	US 2000-741238		20001219 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Horlick, Kenneth R.		
ASSISTANT EXAMINER:	Wilder, Cynthia		
LEGAL REPRESENTATIVE:	Leydig, Voit & Mayer, Ltd.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	23532		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB The present invention provides methods and compositions for the construction of custom cDNA microarrays. In particular, the methods involve the selection of relevant clusters based on knowledge and expression patterns using public database information and the identification of the best representative cDNA clones within the selected cluster. The methods facilitate the construction of custom microarrays suitable for use in any biotechnological art. In preferred embodiments, the present invention provides the the ImmunoChip.

=> d his

(FILE 'HOME' ENTERED AT 15:02:34 ON 24 APR 2008)

FILE 'MEDLINE, BIOSIS, CAPLUS, CA, USPATFULL' ENTERED AT 15:04:03 ON 24
APR 2008

L1 272 S FLOMERFELT OR GRESS
L2 785133 S SPATIAL
L3 785133 S SPATIAL OR (STROMAL (W) PROTEIN (W) ASSOCIATED (W) WITH (W) T
L4 3 S SPATIAL AND (STROMAL (W) PROTEIN (W) ASSOCIATED (W) WITH (W)
L5 2 DUP REM L4 (1 DUPLICATE REMOVED)
L6 3 S STROMAL (W) PROTEIN (W) ASSOCIATED (W) WITH (W) THYMII
L7 6 S SPATIAL AND UBA3
L8 5 DUP REM L7 (1 DUPLICATE REMOVED)

=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 15:11:21 ON 24 APR 2008